Ponatinib after failure of <scp>second‐generation</scp> tyrosine kinase inhibitor in resistant <scp>chronic‐phase</scp> chronic myeloid leukemia-Reference-Cited by-同舟云学术

Ponatinib after failure of second‐generation tyrosine kinase inhibitor in resistant chronic‐phase chronic myeloid leukemia

Published:2022-08-30 Issue:11 Volume:97 Page:1419-1426
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:American J Hematol

Author:

Kantarjian Hagop M.¹^ORCID,Jabbour Elias¹^ORCID,Deininger Michael²,Abruzzese Elisabetta³,Apperley Jane⁴,Cortes Jorge⁵^ORCID,Chuah Charles⁶,DeAngelo Daniel J.⁷,DiPersio John⁸,Hochhaus Andreas⁹,Lipton Jeffrey¹⁰,Nicolini Franck E.¹¹^ORCID,Pinilla‐Ibarz Javier¹²,Rea Delphine¹³,Rosti Gianantonio¹⁴,Rousselot Philippe¹⁵,Shah Neil P.¹⁶,Talpaz Moshe¹⁷^ORCID,Srivastava Shouryadeep¹⁸,Ren Xiaowei¹⁸,Mauro Michael¹⁹

Affiliation:

1. Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA

2. Division of Hematology and Oncology, Department of Medicine University of Utah Huntsman Cancer Institute Salt Lake City Utah USA

3. Division of Hematology, S. Eugenio Hospital Tor Vergata University Rome Italy

4. Centre for Haematology Imperial College London London UK

5. Georgia Cancer Center Augusta Georgia USA

6. Department of Haematology Singapore General Hospital, Duke‐NUS Medical School Singapore Singapore

7. Department of Medical Oncology Dana‐Farber Cancer Institute Boston Massachusetts USA

8. Division of Oncology Washington University School of Medicine St. Louis Missouri USA

9. Department of Hematology/Oncology Universitätsklinikum Jena Jena Germany

10. Princess Margaret Cancer Centre Toronto Ontario Canada

11. Centre Leon Berard, Department d'Hématologie & INSERM U1052 Equipe BMP, Niche Tumorale et Resistance, CRCL Lyon France

12. H. Lee Moffitt Cancer Center & Research Institute Tampa Florida USA

13. Department of Hematology Hopital Saint‐Louis Paris France

14. IRST/IRCCS “Dino Amadori” Meldola Province of Forlì‐Cesena Italy

15. Hospital Mignot University de Versailles Saint‐Quentin‐en‐Yvelines Paris France

16. Department of Medicine (Hematology/Oncology) University of California San Francisco San Francisco California USA

17. Comprehensive Cancer Center University of Michigan Ann Arbor Michigan USA

18. Takeda Development Center Americas, Inc. Lexington Massachusetts USA

19. Memorial Sloan Kettering Cancer Center New York New York USA

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.26686

Reference22 articles.

1. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring

2. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring

3. Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia

4. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia

5. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 25 years of experience in the treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: results, opportunities, questions;Meditsinskiy sovet = Medical Council;2024-01-17

2. The anti-leukemia activity and mechanisms of shikonin: a mini review;Frontiers in Pharmacology;2023-11-02

3. Comparative efficacy and safety of different doses of ponatinib versus other tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia: a systematic review and network meta-analysis;Expert Opinion on Drug Safety;2023-10-18

4. Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events;Blood Cancer Journal;2023-08-11

5. Dose optimisation of ponatinib in chronic phase chronic myeloid leukemia;Expert Review of Hematology;2023-07-27